AstraZeneca Presents Imfinzi (durvalumab) Plus tremelimumab Combination Data at AACR Annual Meeting
Phase Ib Study 006 long-term follow-up shows clinical activity in PD-L1 greater than or equal to 25% and less than 25% groups in 2nd-line non-small cell lung cancer
Phase I Study 10 data shows clinical activity with combination treatment in 2nd-line metastatic urothelial carcinoma
CAMBRIDGE, United Kingdom, April 16, 2018 (GLOBE NEWSWIRE) -- AstraZeneca and MedImmune, its global biologics research and development arm, today presented efficacy and safety data from two Phase I trials evaluating Imfinzi (durvalumab) in combination with tremelimumab in 2nd-line immunotherapy-naïve patients with either non-squamous advanced non-small cell lung cancer (NSCLC) (Study 006) or metastatic urothelial carcinoma (mUC) (Study 10).1,2 The data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2018.
Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: "The mature data sets from these Phase I trials help further characterise the overall survival of durvalumab plus tremelimumab combination in 2nd-line non-squamous non-small cell lung cancer and 2nd-line metastatic urothelial carcinoma. We look forward to exploring whether OS is distinguished from durvalumab monotherapy in our Phase III MYSTIC and DANUBE trials, expected to read out later this year and next year, respectively."
Study 006: Safety and activity of 2nd-line
+ tremelimumab in non-squamous advanced NSCLC
The Study 006 long-term follow-up results showed clinical activity in both PD-L1 greater than or equal to 25% and less than 25% groups.1 Tumour PD-L1 expression was assessed with the Ventana PD-L1 (SP263) assay, PD-L1 cut-off: greater than or equal to 25% of tumour cells with membrane staining.1 The table below shows anti-tumour activity and survival by PD-L1 status.1
|Response and survival||
PD-L1 greater than or equal to 25%
N = 57
PD-L1 less than 25%
N = 136
N = 213
|Complete Response (CR)||1 (1.8)||0||1 (0.5)|
|Partial Response (PR)||19 (33.3)||16 (11.8)||39 (18.3)|
|Stable Disease (SD)||17 (29.8)||55 (40.4)||77 (36.2)|
|Progressive Disease (PD)||16 (28.1)||52 (38.2)||77 (36.2)|
Objective Response Rate (ORR)
(CR + PR)
| 20 (35.1)
Duration of Response (DOR)
12-month OS, %
|Note: Investigator-assessed anti-tumour activity according to RECIST v1.1. NE, not estimable.
a20 patients had unknown PD-L1 expression
The combination of durvalumab and tremelimumab demonstrated a manageable safety profile in patients with advanced NSCLC.1 The most common treatment-related adverse events (AEs) were fatigue (19%), pruritus (17%), diarrhoea (15%), reduced appetite (14%) and rash (14%).1 14 patients (7%) experienced a treatment-related AE that led to treatment discontinuation, and 23% experienced a Grade 3/4 treatment-related AE.1 There was one treatment-related death (multifactorial hypoxia).1
+ tremelimumab in patients with metastatic urothelial cancer
The combination of durvalumab plus tremelimumab showed clinical activity in previously treated mUC, regardless of PD-L1 status.3 Tumour and immune-cell PD-L1 expression was assessed with the Ventana PD-L1 (SP263) assay, PD-L1 cut-off: greater than or equal to 25% of tumour and immune cells with membrane staining.2 The table below shows anti-tumour activity and survival by PD-L1 status.3
|Response and survival||
PD-L1 greater than or equal to 25%
PD-L1 less than 25%
Confirmed Objective Response Rate (ORR)
(CR+PR) (95% CI), %
|29.4 (19.0-41.7)||15.1 (8.3-24.5)||14.3 (1.8-42.8)||20.8 (15.0-27.8)|
|Ongoing ORR, %||60.0||92.3||100||74.3|
Disease Control Rate (DCR)
(CR+PR+SD greater than or equal to 24 weeks) (95% CI), %
|32.4 (21.5-44.8)||24.4 (15.8-34.9)||42.9 (17.7-71.1)||29.2 (22.4-36.7)|
Median PFS, months (95% CI)
PFS 6-month rate
Median OS, months (95% CI) *
OS 6-month rate
|NE = not estimable
*Should be interpreted with caution due to limited follow-up at data cut-off
The combination of durvalumab and tremelimumab demonstrated a manageable safety profile in patients with mUC.2 Treatment-related AEs occurred in 76% of patients and were Grade 3-4 in 29%.2 The most common treatment-related AEs were pruritus (26%), fatigue (24%), diarrhoea (20%), rash (14%) and increased lipase (12%). Treatment-related AEs led to discontinuation of therapy in 12% of patients.2 There was one treatment-related death (pulmonary haemorrhage).2
NOTES TO EDITORS
For more information on AstraZeneca at AACR, please visit www.twitter.com/AstraZeneca.
Imfinzi (durvalumab) is a human monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses.4-7
In February 2018, durvalumab received US FDA approval for the treatment of patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. Durvalumab also received accelerated approval in the US for the treatment of patients with locally advanced or metastatic urothelial carcinoma, who have disease progression during or following platinum-containing chemotherapy, or whose disease has progressed within 12 months of receiving platinum-containing chemotherapy before (neoadjuvant) or after (adjuvant) surgery.8
As part of a broad development programme, durvalumab is also being investigated as a monotherapy and/or in combination with tremelimumab, an anti-CTLA-4 monoclonal antibody, as a first line treatment for patients with NSCLC, small cell lung cancer, locally advanced or metastatic urothelial carcinoma, head and neck cancer and other solid tumours.9
Tremelimumab is an investigational human monoclonal antibody that targets the activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Tremelimumab blocks the activity of CTLA-4, contributing to T cell activation and boosting the immune response to cancer.10-12 Tremelimumab is being investigated in an extensive clinical trial programme in combination with durvalumab, in NSCLC, locally-advanced or metastatic urothelial carcinoma, head and neck cancer, liver cancer and blood cancers.9
About AstraZeneca's Approach to Immuno-Oncology
Immuno-Oncology (IO) is a therapeutic approach designed to stimulate the body's immune system to attack tumours. At AstraZeneca and MedImmune, our biologics research and development arm, our IO portfolio is anchored by immunotherapies that have been designed to overcome anti-tumour immune suppression. We believe that IO-based therapies will offer the potential for life-changing cancer treatments for the clear majority of patients.
We are pursuing a comprehensive clinical-trial programme that includes durvalumab (anti-PD-L1) as monotherapy and in combination with tremelimumab (anti-CTLA-4) in multiple tumour types, stages of disease, and lines of therapy, using the PD-L1 biomarker as a decision-making tool to define the best potential treatment path for a patient. In addition, the ability to combine our IO portfolio with small, targeted molecules from across our Oncology pipeline, and with those of our research partners, may provide new treatment options across a broad range of tumours.
About AstraZeneca in Oncology
AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly-growing portfolio of new medicines that has the potential to transform patients' lives and the Company's future. With at least six new medicines to be launched between 2014 and 2020, and a broad pipeline of small molecules and biologics in development, we are committed to advance Oncology as a growth platform for AstraZeneca, focused on lung, ovarian, breast and blood cancers. In addition to our core capabilities, we actively pursue innovative partnerships and investments that accelerate the delivery of our strategy as illustrated by our investment in Acerta Pharma in haematology.
By harnessing the power of four scientific platforms - Immuno-Oncology, Tumour Drivers and Resistance, DNA Damage Response and Antibody Drug Conjugates - and by championing the development of personalised combinations, AstraZeneca has the vision to redefine cancer treatment and, one day, eliminate cancer as a cause of death.
MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of small-molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across Oncology; Respiratory; Cardiovascular, Renal & Metabolic Diseases; and Infection and Vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca's three global R&D centres, with additional sites in Cambridge, UK, and Mountain View, CA. For more information, please visit www.medimmune.com.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company is also selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
This press release is issued from AstraZeneca Corporate Headquarters in Cambridge, UK and is intended to provide information about our global business for health specialist or medical media. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where AstraZeneca conducts business.
|Karen Birmingham||+44 203 749 5634|
|Eleanor Duff||+1 301 398 0967|
|Hugues Joublin||+1 301 398 3041|
- Chaft, J et al. Safety and activity of second-line durvalumab + tremelimumab in non-squamous advanced NSCLC. To be presented at AACR 2018, April 14-18, 2018. Chicago, IL.
- Balar, A et al. Durvalumab + tremelimumab in patients with metastatic urothelial cancer. To be presented at AACR 2018, April 14-18, 2018. Chicago, IL.
- Balar, A et al. "Durvalumab + tremelimumab in patients with metastatic urothelial cancer." Abstract. To be presented at AACR 2018, April 14-18, 2018. Chicago, IL.
- Stewart R, et al. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. Cancer Immunol Res; 2015. Published OnlineFirst May 5, 2015; doi: 10.1158/2326-606.
- Patel S P and Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther; 14(4) April 2015:847-856.
- Haile S et al. Tumor Cell Programmed Death Ligand 1-Mediated T Cell Suppression Is Overcome by Coexpression of CD80. J Immunol 2011; 186: 6822-6829.
- Haile S et al. Soluble CD80 Restores T Cell Activation and Overcomes Tumor Cell Programmed Death Ligand 1-Mediated Immune Suppression. J Immunol 2013; 191: 2829-2836.
- US FDA. US Imfinzi (durvalumab) prescribing information. February 2018.
- AstraZeneca. Clinical Trials Appendix Full-year and Q4 2017 Results Update. Available at: https://www.astrazeneca.com/content/dam/az/PDF/2017/Full-Year/Full-Year%202017%20Results%20Clinical%20trials%20appendix.pdf. Accessed Apr. 2018
- Bograd AJ, et al. Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. Cancer Immunol Immunother. 2011;60(11):1509-27.
- Lee et al. Novel antibodies targeting immune regulatory checkpoints for cancer therapy. Br J Clin Pharmacol. 2013;76(2):233-47.
- Eroglu, et al. Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. Eur J Cancer. 2015;51(17):2689-97
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: AstraZeneca via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Forterra Announces First Quarter 2018 Earnings Schedule24.4.2018 12:00 | Pressmeddelande
IRVING, Texas, April 24, 2018 (GLOBE NEWSWIRE) -- Forterra, Inc. ("Forterra") (Nasdaq:FRTA) plans to release first quarter 2018 financial results before the market open on Tuesday, May 8, 2018. A conference call to review financial results will also be held on Tuesday, May 8, 2018 at 8:30 a.m. Eastern time (7:30 a.m. Central). Hosting the call will be Jeff Bradley, Chief Executive Officer, and Charlie Brown, Executive Vice President and Chief Financial Officer. CONFERENCE CALL AND WEBCAST DETAILS Webcast Information Event: Q1 2018 Forterra, Inc. Earnings Call Date: Tuesday, May 8, 2018 Time: 8:30 a.m. Eastern Time (7:30 a.m. Central) https://edge.media-server.com/m6/p/a3wzhe79 Conference Call Information U.S.: 1-574-990-1396 Toll-Free: 1-844-498-0572 Participant Passcode: 6398379 Replay Information A replay of the conference call and archive of the webcast will be available within 24 hours after the call on the "Events & Presentations" page under the Investor section of the Company's w
Meltwater acquires leading social analytics company Sysomos24.4.2018 10:00 | Pressmeddelande
Acquisition expands Meltwater's ability to incorporate online news and data with social media analytics in one robust platform SAN FRANCISCO, April 24, 2018 (GLOBE NEWSWIRE) -- Meltwater, a pioneer of media intelligence and now Outside Insight, today announced its acquisition of Sysomos, a leader in social analytics and engagement. The addition of Sysomos to Meltwater enables organizations to analyze social media, news and other human-generated content in one platform, furthering Meltwater's mission to give businesses the insights from outside data, helping them stay ahead. "All the social analytics companies look at social data in isolation, limiting the insights for brands and businesses," says Jorn Lyseggen, founder and CEO of Meltwater. "With our acquisition of Sysomos, we can bring together news and social media under one company, giving social data context while adding social engagement to our news and media monitoring offering." For the PR and communications teams who engage wit
New leaders emerge in 2018 All-Europe trading team ranking24.4.2018 10:00 | Pressmeddelande
NEW YORK, April 24, 2018 (GLOBE NEWSWIRE) -- Competition in electronic trading is becoming fierce as global trade execution teams re-position themselves for delivering their solutions at scale in a post MiFID II regulatory environment. J.P. Morgan continues to dominate claiming first place in electronic trading, for a second consecutive year, according to Institutional Investor's All-Europe Trading Team survey. Meanwhile Bank of America Merrill Lynch took home second place, up two spots from fourth place last year; a significant move for Bank of America Merrill Lynch, which bumped its peers Credit Suisse in third place and UBS in fourth place to win the No. 2 position. The two-rung move is a marked shift away from its previous high-touch leadership and is an endorsement that the bank's investments in technology are resonating with clients. In high-touch trading, UBS leapt to No. 1 swapping its fifth place position last year with Bank of America Merrill Lynch, who took fifth in the high
BT Dials in Corvil Analytics to Help Achieve World-Class Service Delivery for World's Largest Virtual Contact Centre24.4.2018 10:00 | Pressmeddelande
Corvil empowers BT with the visibility and insight to achieve outstanding caller experience for a public sector customer serving 20M+ citizens DUBLIN, Ireland, April 24, 2018 (GLOBE NEWSWIRE) -- Corvil today announced that BT Global Services has deployed Corvil Analytics to manage and optimise VoIP call quality of one of the largest contact centres in the world channelling its services through 30,000 agents across 180 sites. As a leading provider of contact centre solutions globally, BT has a strong track-record in designing and implementing large-scale transformational engagements. Looking to simplify service assurance and maintain call quality excellence in an environment where call volumes continually reach 12500 concurrent calls (12 new calls per second), BT sought to enlist an analytics partner. In a climate of intense scrutiny on public sector performance and with stringent customer Service Level Agreements (SLAs) in place, BT selected Corvil to help improve caller experience by
MedicCoin Unveils International Adoption Strategy Based on Integrating Blockchain Technology into Everyday Life24.4.2018 09:00 | Pressmeddelande
Strategy focuses on improving health of mankind through blockchain-powered rewards, advancing scientific research and charitable donations NEW YORK, April 24, 2018 (GLOBE NEWSWIRE) -- via NetworkWire -- MedicCoin, a community-driven crypto focused on improving the lives of millions worldwide, today provides the multifaceted roadmap established for global adoption while recapping practical innovations that set MedicCoin apart for everyday use. Introducing Multiple Ways to Earn Crypto as a Reward for Positive Choices The MedicCoin founders envisioned using blockchain technology to make life better for all mankind. A key part of staying true to this vision is ensuring people around the world can join the MedicCoin community without highly technical skills or expensive mining equipment. Living an Active Lifestyle By simply installing the MedicWalk app and staying active, anyone will be able to acquire MedicCoin. MedicWalk will be launched within the next few weeks. Donating Unused Computer
In-Memory Computing Summit Europe Announces Full Breakout Session Schedule24.4.2018 09:00 | Pressmeddelande
Register by April 29th to Receive a 30 Percent Discount FOSTER CITY, Calif., April 24, 2018 (GLOBE NEWSWIRE) -- GridGain Systems, provider of enterprise-grade in-memory computing platform solutions based on Apache® Ignite(TM), today released the full breakout session schedule for the second annual In-Memory Computing Summit® Europe, the premier conference for individuals from Europe and Asia that are currently using or exploring using in-memory computing. Conference breakout sessions are in five tracks: Tales from the Trenches, New Capabilities, Architecture, Streaming Data, and Hardware. Speakers include representatives from companies such as Oracle, Intel, NEC Corporation of America, GridGain Systems, Hazelcast, iguazio, Neeve Research, ScaleOut Software, Software AG, Bouquet.ai, and VoltDB. The IMC Summit Europe will take place at the Park Plaza Victoria London, June 25-26, 2018. Attendees can receive a 30 percent Super Saver discount off the full price registration fee by purchasin
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum